Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2025-01-15 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
第五届董事会独立董事2025年第一次专门会议决议
Board/Management Information Classification · 95% confidence The document is titled as a resolution from the independent directors of the fifth board of directors of the company, dated January 12, 2025. It details the convening of a special meeting of independent directors, the attendance, and the approval of specific proposals related to daily related-party transactions and foreign exchange hedging business. There is no financial data, no mention of annual or quarterly financial results, no audit report, no earnings release, no merger or acquisition activity, and no shareholder voting results. The document is a formal board/management announcement about internal governance matters and approvals by independent directors. Therefore, it fits best under Board/Management Information (MANG). The document length is short (1154 characters), and it is not an announcement of a report publication but a meeting resolution. Hence, the classification is MANG with high confidence.
2025-01-15 Chinese
关于开展外汇套期保值业务的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by a company regarding its decision to engage in foreign exchange hedging activities. It details the purpose, amount, transaction types, risk analysis, risk control measures, accounting treatment, and approvals by the board and supervisory committee. The document is a formal disclosure of a new financial activity and its governance, not a financial report or earnings release. It is not a report publication announcement since it contains substantive information about the transaction and approvals. It is not a management change, capital update, or legal proceeding. The document fits best as a Regulatory Filing (RNS) because it is a regulatory announcement about a new financial risk management activity that does not fit other specific categories.
2025-01-15 Chinese
第五届董事会第二十五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 25th meeting of the 5th Board of Directors of the company. It details the meeting attendance, voting results, and decisions made regarding related party transactions, bank credit applications, and foreign exchange hedging business. The document does not contain financial statements or detailed financial data but rather reports on board decisions and approvals. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors or senior management. The document length is short (1588 characters), and it is not a report publication announcement or regulatory filing. Therefore, the classification is MANG with high confidence.
2025-01-15 Chinese
关于2024年第四季度健帆转债转股情况的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company regarding the conversion of its convertible bonds into shares during the fourth quarter of 2024. It details the bond issuance, conversion prices adjustments, the number of bonds converted, remaining bonds, and the impact on the company's share capital structure. The document is titled as an "announcement" and contains specific data about bond conversions and share capital changes. It does not contain comprehensive financial statements or detailed financial performance analysis typical of an Interim/Quarterly Report (IR) or Annual Report (10-K). Instead, it is a regulatory announcement about bond conversion and share capital changes, which fits best under the category of Capital/Financing Update (CAP). The document length is 4562 characters, which is sufficient to provide substantive information rather than just a brief notice. Therefore, the classification is Capital/Financing Update (CAP).
2025-01-03 Chinese
关于全资子公司产品获得欧盟MDR认证的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company about its wholly-owned subsidiary's product receiving EU MDR certification. It details the certification specifics, product description, impact on the company, and risk warnings. The document is short (1197 characters) and does not contain financial statements, management discussion, or detailed financial data. It is an announcement of a regulatory approval event rather than a financial report or management update. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a voting result, board change, or legal proceeding. The content is a regulatory announcement about product certification, which is best classified under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2024-12-12 Chinese
第五届董事会第二十四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 24th meeting of the 5th Board of Directors of the company. It details the meeting attendance, the agenda discussed, and the voting results on a specific proposal regarding the company's market value management system. There is no financial data, no report attached or referenced as being published, and no mention of an annual or interim report. The content focuses on board decisions and governance matters. Therefore, this document fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors.
2024-12-10 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.